| 证券代码 | RCUS.N |
| 证券名称 | Arcus Biosciences Inc |
| 证券类型 | 美股 |
| 上市场所 | 纽约证券交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2018-03-15 |
| 首发价格(元) | 15 USD |
| 首发数量(股) | 8000000 |
| 首发募资额(元) | 120,000,000.00 USD |
| 首发主承销商 | Citigroup Global Markets Inc.,Goldman Sachs & Co. LLC,Leerink Pa |
| 货币单位 | USD |
| 公司名称 | Arcus Biosciences, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 3928 Point Eden Way, Hayward, California, USA |
| 成立日期 | 2015-04-30 |
| 董事会主席 | - |
| 公司属地 | United States 美国 |
| 公司网址 | www.arcusbio.com |
| 电话 | +1 (510) 694-6200 |
| 传真 | - |
| 公司简介 | Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies by leveraging underexploited biological opportunities. Specifically, the company targets well-characterized biological pathways with significant scientific data supporting their importance in regulating the immune response against cancer and for which either there are no molecules in development or those that exist have suboptimal profiles. To exploit these pathways, they have built a robust and highly efficient discovery capability to create and optimize highly differentiated small-molecule immuno-oncology product candidates. |